Lyell(LYEL) - 2023 Q4 - Annual Results

Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the fourth quarter and year ended December 31, 2023. "We are focused on generating clinical data in our two Phase 1 ...